Seventure leads Axial's $25M series B

Axial Biotherapeutics Inc. (Boston, Mass.) raised a $25 million series B led by Seventure Partners on the back of its Parkinson's disease and autism microbiome programs.

Existing investors Longwood Fund, Domain Associates and Heritage Medical

Read the full 348 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE